Iberogast for SIBO and Gastroparesis: Does It Actually Work?

If you've spent any time in SIBO communities, you've probably seen Iberogast mentioned as a prokinetic — the class of agents that keep food and bacteria moving through your gut between meals. What you may not know is that Iberogast has a 60-year clinical history in Germany, robust randomized controlled trial data for functional dyspepsia and IBS, and a plausible biological mechanism that makes it genuinely useful as an adjunct in SIBO management. It's also had its share of controversy: rare but serious liver toxicity cases led to regulatory warnings in several countries. This guide cuts through the noise and gives you an honest, evidence-based look at what Iberogast can and can't do for SIBO and gastroparesis.

What Is Iberogast (STW 5)?

Iberogast, also known by its technical designation STW 5, is a proprietary liquid herbal extract developed in Germany by Steigerwald Arzneimittelwerk in the 1960s. The formula contains standardized ethanol extracts of nine medicinal plants: bitter candytuft (Iberis amara, which gives the product its name), angelica root, milk thistle fruit, greater celandine herb, caraway fruit, licorice root, peppermint leaves, greater celandine, and chamomile flower. Each of these herbs has been selected for a specific pharmacological contribution to the overall formula.

In Germany, Austria, and Switzerland, Iberogast is registered as a pharmaceutical product and is widely prescribed by gastroenterologists for functional dyspepsia, irritable bowel syndrome, and related conditions. In the United States, it's sold as a dietary supplement and is available over the counter, which means it's not subject to the same regulatory scrutiny as pharmaceutical drugs. This regulatory difference matters when interpreting the evidence — the product sold in Germany is a standardized pharmaceutical preparation, while what's available in the US may vary in quality.

Mechanism of Action: Prokinetic and Antispasmodic in One

What makes Iberogast pharmacologically interesting is that it acts on gut motility through multiple simultaneous pathways — it can be prokinetic (speeding up gut transit) and antispasmodic (reducing excessive cramping) depending on the state of the gut at any given moment. This dual action is sometimes described as 'normalizing' motility rather than simply accelerating or slowing it.

Clinical Evidence: What Does the Research Actually Show?

Iberogast has more clinical trial data behind it than almost any other herbal GI product on the market. A 2004 Cochrane-style systematic review and multiple subsequent RCTs have consistently demonstrated its superiority over placebo for functional dyspepsia (unexplained upper GI symptoms) and IBS. A pivotal RCT published in the American Journal of Gastroenterology found that STW 5 was significantly more effective than placebo for reducing the composite symptom score in functional dyspepsia, with an effect size comparable to pharmaceutical prokinetics like cisapride.

For gastroparesis specifically — the condition where the stomach empties too slowly, often due to vagal nerve damage or diabetes — evidence is more limited but promising. A 2015 study found STW 5 accelerated gastric emptying in patients with functional dyspepsia and delayed gastric emptying, comparable to the effect of domperidone in that study's subgroup analysis. For SIBO specifically, there are no large RCTs using Iberogast as the primary prokinetic. The rationale for its use in SIBO is mechanistic (MMC stimulation) and extrapolated from the broader prokinetic evidence base.

Using Iberogast as a Prokinetic for SIBO

In the SIBO world, prokinetics are used primarily after antimicrobial treatment — whether pharmaceutical (rifaximin, neomycin, metronidazole) or herbal (berberine, oregano oil, allicin) — to restore MMC function and reduce the risk of bacterial regrowth. The standard approach is to begin prokinetic therapy at the start of antimicrobial treatment or immediately after completing it, and continue for 3-6 months.

The standard dosing protocol for Iberogast as a prokinetic in SIBO management is 20 drops (approximately 1 mL) in a small amount of warm water, taken three times daily before or with meals. Some practitioners dose it twice daily for patients who find three times daily inconvenient. The liquid format, while unusual for US consumers accustomed to capsules, actually offers the advantage of rapid mucosal contact in the upper GI tract, which may be relevant for its gastric motility effects.

The Liver Toxicity Controversy: What You Need to Know

Iberogast's safety record has one notable blemish: greater celandine (Chelidonium majus), one of the nine herbs in the formula, contains chelidonine and other alkaloids that have been associated with rare cases of hepatotoxicity (liver toxicity). The original STW 5 formula contained greater celandine; a modified version called STW 5-II was developed with reduced celandine content in response to safety concerns.

The Australian Therapeutic Goods Administration (TGA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have both issued warnings about Iberogast and liver toxicity, based on case reports of acute hepatitis in users. The majority of cases resolved after stopping the product, but at least one fatality has been reported in association with herbal products containing Chelidonium majus. It's important to note that causality is not definitively established in all cases, and the incidence appears to be very low (estimated at fewer than 1 in 100,000 users). Nevertheless, the risk is real enough that periodic liver enzyme monitoring is prudent for long-term users, and anyone with pre-existing liver disease should avoid Iberogast entirely.

Alternative Herbal Prokinetics to Consider

If Iberogast's liver toxicity concern makes you hesitant — and it's a reasonable concern — there are several alternative herbal and nutraceutical prokinetics worth considering. Ginger (Zingiber officinale) at doses of 500-1000 mg before meals has good evidence for accelerating gastric emptying and stimulating 5-HT4 receptors, with an excellent safety profile. Artichoke leaf extract (Cynara scolymus) has evidence for functional dyspepsia and combines well with ginger in products like Motility Activator. 5-HTP (5-hydroxytryptophan), a serotonin precursor, supports serotonin-mediated gut motility when taken between meals and is a core ingredient in MotilPro.

Low-dose naltrexone (LDN) is a prescription prokinetic option increasingly used by SIBO-literate physicians for patients with impaired MMC function. Prucalopride (Motegrity) is the most evidence-backed prescription prokinetic for SIBO prevention, acting as a selective 5-HT4 agonist. Low-dose erythromycin (50-75 mg at bedtime) is another prescription option that mimics motilin. If Iberogast isn't the right fit, you have options — discuss them with your gastroenterologist or SIBO specialist.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.